Press coverage about Diplomat Pharmacy (NYSE:DPLO) has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.9274303307791 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
A number of brokerages have recently issued reports on DPLO. Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the company a “hold” rating in a research note on Tuesday. TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub downgraded Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 17th. Finally, Needham & Company LLC started coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They set a “buy” rating and a $19.75 price target for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Diplomat Pharmacy has a consensus rating of “Hold” and a consensus price target of $19.36.
Diplomat Pharmacy (NYSE:DPLO) traded down 2.21% on Thursday, reaching $20.76. The company’s stock had a trading volume of 386,726 shares. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $25.09. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 113.44 and a beta of 0.74. The stock has a 50 day moving average price of $20.36 and a 200-day moving average price of $17.41.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a net margin of 0.31% and a return on equity of 2.29%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.23 EPS. Equities analysts predict that Diplomat Pharmacy will post $0.75 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/26/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-diplomat-pharmacy-dplo-stock-price.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc and related companies with MarketBeat.com's FREE daily email newsletter.